Oct 30 (Reuters) - Hip implant maker Zimmer Biomet (ZBH.N), opens new tab lowered its annual profit forecast on Wednesday following last month's disruptions to a software platform that was ...

Also Read: Zimmer Biomet To Stop Selling CPT Hip Implant System By End Of 2024 Due To High Fracture Risks Sports Medicine products generated sales of $454.2 million, up 7.3%. “We are pleased ...

RBC Capital analyst Shagun Singh Chadha maintained a Buy rating on Zimmer Biomet Holdings (ZBH – Research Report) today and set a price ...

In a report released yesterday, Richard Newitter from Truist Financial maintained a Hold rating on Zimmer Biomet Holdings (ZBH – Research ...

Zimmer Biomet now expects 2024 adjusted profit between $7.95 and $8.05 per share, down from its prior forecast range of $8.00 to $8.15 per share. It also forecast annual revenue to grow between 3. ...

we have already seen some conversions of customers that have come to Zimmer Biomet to use that type of robotic application with the world’s number one implant in knees. The partnership is giving ...

Q3 2024 Earnings Call Transcript October 30, 2024 Zimmer Biomet Holdings, Inc. misses on earnings expectations. Reported EPS is $1.74 EPS, expectations were $1.75. Operator: Good morning, ladies and ...

President and Chief Executive Officer of Zimmer Biomet. "Through a series of strategic acquisitions and in-house innovations, we've curated a diversified portfolio of hip implant solutions and ...

Here are five FDA alerts and recalls from 2024 for orthopedic and spine specialists to know: ...

The global hips & knees reconstructive market, valued at USD 20.8 billion in 2022, is expected to experience steady growth ...

We see little to make us nervous about Smith & Nephew's financial flexibility. While the firm has periodically made acquisitions, it has also generated enough cash to deleverage in relatively quick ...